Valink Therapeutics alternatives
9 products to explore · 2026
Your shortlist, at a glance.
Read the comparisons ↓Check each product’s website for current pricing and features. A verified badge indicates a verified listing, not a ranking.
About Valink Therapeutics and its alternatives
Users searching for Valink Therapeutics alternatives are typically exploring next-generation bispecific or logic-gated ADC platforms that can address drug resistance and expand treatable indications while reducing off-target toxicity. Valink stands out with its V-Gate technology that tunes binding to continuous target levels rather than simple AND/OR logic, powered by the LiliumX platform integrating synthetic biology, screening and AI. Competitors range from established ADC developers with approved products to emerging biotechs building similar gated or bispecific constructs. Key decision factors include clinical-stage assets, payload flexibility, tumour selectivity data and partnership models. This page compares Valink to leading ADC-focused companies on pipeline maturity, technology differentiation and development focus so researchers and investors can evaluate the most suitable options for specific oncology programs.
Explore the alternatives
- F
1.Farxiga
Healthcare & MedicalEnhertu is AstraZeneca and Daiichi Sankyo's approved HER2-directed ADC used across multiple solid tumours. It offers strong clinical efficacy and a cleavable linker but relies on single-antigen targeting without logic gating. Compared with Valink Therapeutics, Enhertu has far greater clinical validation and commercial scale while Valink's V-Gate bispecific design seeks improved selectivity and resistance overcoming in earlier discovery stages.
2.Gilead Sciences (Kite Pharma)
Healthcare & MedicalTrodelvy is Gilead's TROP-2 directed ADC approved for breast and urothelial cancers. It uses a moderately toxic payload and standard targeting. Versus Valink, Trodelvy provides real-world use data and broader indications today, whereas Valink's dual-target V-Gate approach aims for tighter tumour restriction and new payload opportunities not yet clinically tested.
3.Adcetris
Healthcare & MedicalAdcetris (brentuximab vedotin) from Seagen/Pfizer was one of the first approved ADCs targeting CD30 in lymphomas. It demonstrates durable responses but faces resistance issues common to single-target ADCs. Valink Therapeutics positions its bispecific V-Gate candidates as potential solutions for similar resistance mechanisms through multi-antigen logic in solid tumours where Adcetris is not indicated.
4.Roche Ventana
Healthcare & MedicalPolivy is Roche's CD79b-targeted ADC approved for diffuse large B-cell lymphoma in combination regimens. It shows strong activity in hematologic malignancies. Valink focuses on solid tumour programs with continuous-level gating technology that Polivy lacks, targeting different biology and tissue distribution challenges.
5.Blenrep
Healthcare & MedicalGSK's Blenrep is a BCMA-directed ADC for multiple myeloma that was later withdrawn in some markets due to safety concerns. Its experience highlights the need for improved selectivity. Valink's V-Gate platform is designed to enhance tumour-versus-healthy discrimination, potentially mitigating similar toxicity risks in future ADCs.
6.Mersana Therapeutics
Healthcare & MedicalMersana develops next-generation ADCs with novel payloads and linkers, including Dolasynthen and Immunosynthen platforms. Their work emphasises tolerability and new targets. Compared with Valink, Mersana has more disclosed clinical assets while Valink's LiliumX AI engine and V-Gate logic provide a differentiated discovery approach for bispecific constructs.
7.Sutro Biopharma
Healthcare & MedicalSutro uses cell-free expression to create homogeneous ADCs and bispecifics with precise conjugation. Their pipeline includes several oncology candidates. Valink similarly pursues bispecific ADCs but adds continuous-level gating and an integrated AI screening platform that Sutro's technology does not explicitly feature.
- I
8.ImmunoGen
Healthcare & MedicalImmunoGen specialises in ADCs with maytansinoid and IGN payloads and has an approved product in ovarian cancer. Its focus remains largely single-antigen. Valink differentiates by developing dual-target V-Gate molecules intended to expand the addressable patient population beyond what ImmunoGen's current portfolio targets.
9.Zymeworks
Healthcare & MedicalZymeworks develops multifunctional biotherapeutics including bispecific ADCs via its Azymetric and ZymeLink platforms. It has partnerships and clinical programs. Relative to Valink, Zymeworks offers more advanced clinical-stage bispecific assets while Valink emphasises AI-driven exploration of continuous-level gating logic for solid tumours.
See more comparisons in Healthcare & Medical alternatives.
Questions about Valink Therapeutics alternatives
How does Valink Therapeutics V-Gate differ from standard bispecific ADCs?
Valink's V-Gate goes beyond binary AND/OR gating by responding to continuous levels of two targets, allowing finer tuning of binding affinity in cancer versus healthy cells and potentially enabling new indications current ADCs cannot safely treat.
What is the LiliumX platform and why does it matter for ADC discovery?
LiliumX combines synthetic protein biology, high-throughput functional screening and AI to broadly explore bispecific ADC space, identifying candidates that conventional methods miss and accelerating lead optimisation for Valink's oncology programs.
Which cancers is Valink Therapeutics currently targeting in its pipeline?
Valink's pipeline focuses on colorectal cancer, non-small cell lung cancer and other solid tumours, with programs spanning discovery through preclinical stages using their gated bispecific ADC designs.
Are there clinical-stage alternatives to Valink's bispecific ADC approach?
Several companies have clinical bispecific or conditionally active ADCs, but most rely on different gating mechanisms or single-target enhancements; Valink differentiates through continuous-level V-Gate logic and its integrated AI discovery engine.
How does Valink Therapeutics compare on pipeline maturity to larger ADC developers?
Valink remains preclinical with three programs, whereas larger players have approved ADCs and multiple Phase 3 assets; however Valink's platform aims to unlock targets and payloads inaccessible to current approved therapies.
What financing and partnerships has Valink Therapeutics announced recently?
Valink closed an $11.8M pre-A round and formed a strategic alliance with Nona Biosciences to accelerate biologics discovery, supporting advancement of its V-Gate ADC pipeline.